NCT04085029: Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have planned to receive, currently receiving, or have completed hypofractionated image guided radiotherapy (ablative radiotherapy) to site outside of the brain

Comments are closed.

Up ↑